Histone deacetylase inhibitors (HDIs) have progressed rapidly from the laboratory to clinical testing as novel anticancer agents, culminating in the approval of SAHA (Vorinostat, Merck, Whitehouse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback